▼ bearish
Impact
PhasePhase 3 (completed — two of three Phase 3 trials failed)
Time to marketUnknown — at least 3-5+ years if a new Phase 3 trial is required, with no guarantee of FDA acceptance of the proposed path
fasedienol Updated Jul 3
What to watch
Fasedienol has now failed two consecutive Phase 3 trials (PALISADE-3 Dec 2025, PALISADE-4 June 2026). The stock traded at ~$2.04 before the PALISADE-4 miss and collapsed to ~$0.25, a ~$10M market cap. The company plans an FDA meeting for a potential new trial path, but the path to approval looks extremely long and uncertain. Watch for dilution risk as the company may need financing to fund any future trial.
Bull case
- Novel first-in-class mechanism (pherine nasal spray) is differentiated from all approved anxiety medications, no systemic side effects, rapid onset within minutes, and no abuse potential like benzodiazepines.
- PALISADE-2 Phase 3 trial did succeed (p=0.015), proving the drug can work. A post-hoc analysis of PALISADE-4 showed nominal significance (p=0.036) in a subgroup with very severe SAD, providing a hypothesis for a more targeted future trial.
- FDA granted Fast Track designation, and the company has received positive FDA feedback on using the LSAS scale as a primary endpoint, the proposed new multi-dose trial design could potentially salvage the program.
Bear case
- Two consecutive Phase 3 failures (PALISADE-3 and PALISADE-4) make it very unlikely the FDA will accept a path forward without another large, costly, and time-consuming trial.
- PALISADE-4 primary endpoint was a decisive miss (p=0.427, far from statistical significance), and all secondary endpoints also failed. The post-hoc subgroup signal is exploratory, not confirmatory, and regulators rarely accept such analyses.
- With a ~$10M market cap, the stock has limited room to fall but also limited ability to raise capital. A new Phase 3 trial would require significant financing, causing severe dilution at current share prices.